Market Place
Sourcing Support
Ocuphire to transform into gene therapy biotech via Opus buyout
23 Oct 2024 //
FIERCE BIOTECH
Ocuphire Pharma Announces Acquisition of Opus Genetics
22 Oct 2024 //
GLOBENEWSWIRE
Ocuphire Publishes Ph 3 Results For RYZUMVI Ophthalmic Solution
30 Sep 2024 //
GLOBENEWSWIRE
Ocuphire Initiates Ph 3 Trial of Phentolamine for Presbyopia
05 Sep 2024 //
GLOBENEWSWIRE
Ocuphire Pharma Announces Q2 2024 Results And Corporate Update
13 Aug 2024 //
GLOBENEWSWIRE
Ocuphire Pharma to Present at Two Investor Conferences in August
08 Aug 2024 //
GLOBENEWSWIRE
Ocuphire To Highlight APX3330 For Diabetic Retinopathy In July
10 Jul 2024 //
GLOBENEWSWIRE
Ocuphire APX3330 Diabetic Retinopathy Data At Retina Meetings
06 Jun 2024 //
GLOBENEWSWIRE
Ocuphire Pharma Q1 2024 Financials, Corporate Update
10 May 2024 //
GLOBENEWSWIRE
Ocuphire`s APX3330 Data Featured At ARVO 2024
06 May 2024 //
GLOBENEWSWIRE
Ocuphire Pharma to Present at the Aegis Virtual Conference
03 May 2024 //
GLOBENEWSWIRE
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
22 Apr 2024 //
GLOBENEWSWIRE
First Patient In LYNX-2 Phase 3 For Phentolamine After Eye Surgery
11 Apr 2024 //
GLOBENEWSWIRE
Ocuphire Announces Financial Results for Fourth Quarter and Full Year 2023
08 Mar 2024 //
GLOBENEWSWIRE
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
23 Feb 2024 //
GLOBENEWSWIRE
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15 Feb 2024 //
GLOBENEWSWIRE
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
14 Feb 2024 //
GLOBENEWSWIRE
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Conference
05 Feb 2024 //
GLOBENEWSWIRE
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24 Jan 2024 //
GLOBENEWSWIRE
Ocuphire Receives FDA Agreement for LYNX-2 Ph 3 Trial of Phentolamine Solution
04 Jan 2024 //
GLOBENEWSWIRE
Ocuphire Pharma Announces Appointment of Joseph Schachle as COO
27 Nov 2023 //
GLOBENEWSWIRE
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
27 Nov 2023 //
GLOBENEWSWIRE
Ocuphire Pharma Announces Financial Results for Third Quarter 2023
13 Nov 2023 //
GLOBENEWSWIRE
Ocuphire Pharma Announces Appointment of George Magrath as CEO
01 Nov 2023 //
GLOBENEWSWIRE
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 Nov 2023 //
GLOBENEWSWIRE
Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase
26 Oct 2023 //
GLOBENEWSWIRE
Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October
06 Oct 2023 //
GLOBENEWSWIRE
Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI
27 Sep 2023 //
GLOBENEWSWIRE
Viatris and Ocuphire`s dilation eye drop Ryzumvi wins FDA nod
27 Sep 2023 //
FIERCE PHARMA
Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences
11 Sep 2023 //
GLOBENEWSWIRE
Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September
07 Sep 2023 //
GLOBENEWSWIRE
Abstract on ZETA-1 Study of APX3330 Receives Award at WIO Summer Symposium
28 Aug 2023 //
GLOBENEWSWIRE
Ocuphire Pharma Announces Financial Results for Second Quarter 2023
11 Aug 2023 //
GLOBENEWSWIRE
Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference
08 Aug 2023 //
GLOBENEWSWIRE
Ocuphire to Present at American Society of Retina Specialists Annual Meeting
26 Jul 2023 //
GLOBENEWSWIRE
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10 Jul 2023 //
GLOBENEWSWIRE
Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session
27 Jun 2023 //
GLOBENEWSWIRE
Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data
21 Jun 2023 //
GLOBENEWSWIRE
Ocuphire Presents APX3330 ZETA-1 Data at Trials at the Summit (CTS) 2023
12 Jun 2023 //
GLOBENEWSWIRE
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule
24 May 2023 //
GLOBENEWSWIRE
Ocuphire Pharma Announces Financial Results for First Quarter 2023
15 May 2023 //
GLOBENEWSWIRE
Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023
02 May 2023 //
GLOBENEWSWIRE
Ocuphire Provides Corporate Update and Reiterates Previous Guidance
25 Apr 2023 //
GLOBENEWSWIRE
Ocuphire Appoints Rick Rodgers as Interim CEO
21 Apr 2023 //
GLOBENEWSWIRE
Ocuphire Pharma Announces Financial Results for 4Q and Year Ended 2022
30 Mar 2023 //
GLOBENEWSWIRE
Ocuphire Announces APX3330 and Nyxol Data Presentations at ARVO 2023
23 Mar 2023 //
GLOBENEWSWIRE
Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings
16 Feb 2023 //
GLOBENEWSWIRE
Ocuphire Announces FDA Acceptance of NDA & PDUFA Date of September 28 for Nyxol
13 Feb 2023 //
GLOBENEWSWIRE
Oral drug for diabetic retinopathy flunks PII, but biotech wants to go into PIII
26 Jan 2023 //
ENDPTS
Ocuphire`s diabetic eye drug misses phase 2 primary endpoint
26 Jan 2023 //
FIERCE BIOTECH
Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330
25 Jan 2023 //
GLOBENEWSWIRE
Ocuphire Announces First Patient Enrolled in VEGA-2 Pivotal PIII Trial of Nyxol
09 Jan 2023 //
GLOBENEWSWIRE
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol
06 Dec 2022 //
GLOBENEWSWIRE
Ocuphire to Present at Five Upcoming Investor/Industry Conferences
21 Nov 2022 //
GLOBENEWSWIRE
Ocuphire Pharma Enters into a Global License Agreement for Nyxol Eye Drops
07 Nov 2022 //
GLOBENEWSWIRE
Ocuphire Pharma Announces Financial Results for Third Quarter 2022
04 Nov 2022 //
GLOBENEWSWIRE
Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol
02 Nov 2022 //
GLOBENEWSWIRE
Ocuphire Announces Presentations on Nyxol and APX3330
24 Oct 2022 //
GLOBENEWSWIRE
Ocuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022
07 Oct 2022 //
GLOBENEWSWIRE
Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330
06 Oct 2022 //
GLOBENEWSWIRE
